Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Open Access
- 29 March 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (3) , e001664
Abstract
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.Keywords
This publication has 48 references indexed in Scilit:
- Hurdles to the Development of Effective HBV Immunotherapies and HCV VaccinesPathogens and Immunity, 2017
- Antitumor activity of nivolumab on hemodialysis after renal allograft rejectionJournal for ImmunoTherapy of Cancer, 2016
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaAnnals of Oncology, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000PLOS ONE, 2015
- Preventing Hepatitis B Reactivation Due to Immunosuppressive Drug TreatmentsJAMA, 2015
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccinationVaccine, 2007
- The Risk of Tuberculosis in Patients with CancerClinical Infectious Diseases, 2006
- Hepatotoxicity Associated With Isoniazid Preventive TherapyJAMA, 1999